Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphoid 1

Interventions

Cyclophosphamide 110fludarabine phosphate 106Busulfan 84Azacitidine 73Peripheral Blood Stem Cell Transplantation 64Mycophenolic Acid 64Antilymphocyte Serum 64Cytarabine 63Tacrolimus 62fludarabine 61Cyclosporine 56Filgrastim 55Whole-Body Irradiation 52Methotrexate 47Melphalan 42Decitabine 42Radiotherapy 37Clofarabine 29Granulocyte Colony-Stimulating Factor 28Cord Blood Stem Cell Transplantation 28Methylprednisolone 24Etoposide 24thymoglobulin 21Thiotepa 21Stem Cell Transplantation 21sargramostim 19Sirolimus 16Alemtuzumab 15Lenalidomide 13Gemtuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myelodysplastic Syndromes × tozasertib × Clear all
NCT00111683 2015-08-25

MK0457 in Patients With Leukemia (0457-003)

Merck Sharp & Dohme LLC

Phase 1 Completed
28 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Lymphoid, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡